Compare CMU & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMU | BEAT |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Investment Managers | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.0M | 58.6M |
| IPO Year | N/A | N/A |
| Metric | CMU | BEAT |
|---|---|---|
| Price | $3.55 | $1.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 67.2K | ★ 379.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $51.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $0.54 |
| 52 Week High | $3.64 | $4.00 |
| Indicator | CMU | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 49.45 |
| Support Level | $3.48 | $1.50 |
| Resistance Level | $3.61 | $1.54 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 27.27 | 57.25 |
Mfs High Yield Municipal Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company invest various top Healthcare companies, Airport, Universities (Secondary Schools), Universities (Dormitories), and many more, out of maximum revenue is gained from Healthcare Hospitals and Long Term Care.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.